CN201558397U - Sustained-releasing amikacin carrying catheter - Google Patents
Sustained-releasing amikacin carrying catheter Download PDFInfo
- Publication number
- CN201558397U CN201558397U CN2009201284005U CN200920128400U CN201558397U CN 201558397 U CN201558397 U CN 201558397U CN 2009201284005 U CN2009201284005 U CN 2009201284005U CN 200920128400 U CN200920128400 U CN 200920128400U CN 201558397 U CN201558397 U CN 201558397U
- Authority
- CN
- China
- Prior art keywords
- amikacin
- catheter
- sustained
- catheter body
- slow release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The utility model discloses a sustained-releasing amikacin carrying catheter which comprises a catheter body (1); the tail of the catheter body (1) is connected with a gas injection branch pipe (4) and a urine outlet tube (5); the catheter is characterized in that an amikacin sustained releasing layer (2) is covered on the outer surface of the catheter body (1); and the amikacin sustained releasing layer (2) is a polylactic acid and polyglycolic acid coating combined with amikacin. The sustained-releasing amikacin carrying catheter plays the role of significantly reducing CAUTI incidence rate, releases amikacin from inside to outside within a certain time, directly kills bacteria around, and solves the technical difficult problem that amikacin cannot resist high temperature.
Description
Technical field
This utility model belongs to medical material, specifically, is the catheter that a kind of outer surface is coated with the slow release amikacin.
Background technology
Conduit is correlated with, and (catheter-associated urinary tract infection CAUTI) is a kind of common hospital infection of indwelling catheter to urinary tract infection.A statistics of the Center for Disease Control shows: urinary tract infection accounts for 42% in the hospital infection that the inpatient is taken place, and occupies the first place of hospital infection.83% belongs to urinary tract infection in the 561 routine hospital infections of attached institute of the Hiroshima University of Japan, and wherein 93% be that indwelling catheter causes.The infections relating that investigation indwelling catheters such as Huo Hongxu cause accounts for 20.8%～30% of hospital infection, is only second to respiratory system infection.In the crowd of indwelling catheter, there is 2%～4% patient that bacteremia and septicemia take place, its case fatality rate can be up to 13%～30%.Because the urinary tract infection that long-term urethral catheterization occurs together is the first cause of paralytic patient death.CAUTI can cause cystitis, prostatitis, acute pyelonephritis, chronic pyelonephritis, even bacteremic serious consequence.CAUTI will increase length of stay 2.4d, and every patient time increase hospitalization cost is more than 2000 dollars, and mortality rate has improved 3 times simultaneously.This shows that CAUTI has not only increased patient's misery, and obviously increased the expense of being in hospital.
Domestic different regions find that to the analysis of urinary tract infection specimen gram negative bacilli is main pathogenic bacterium, and recall rate is up to 56.57%～90.20%.Wherein, the recall rate of escherichia coli is the highest, can reach 54.62%, and the bacterial strain of generation extended spectrum (ESBLs) is about 43%, and is the trend that rises gradually.Nosocomial infection of southwestern hospital pathogenic bacterium cultivation results showed in 2008, and the bacterial strain that produces ESBLs accounts for 66.50% of escherichia coli strain.Though these pathogenic bacterium are to the antibiotic multidrug resistant, but in the large-scale bacterial drug resistance monitoring of provincialism, can find, amikacin still keeps higher responsive rate to gram negative bacilli, and also like this to producing the ESBLs escherichia coli, responsive rate is about about 83.3%.Moreover, the price of amikacin is also extremely cheap, so it is usually as the choice drug for the treatment of urinary tract infection clinically.Amikacin has another name called amikacin, is a kind of aminoglycoside antibiotics, clinical commonly used be the sulphuric acid preparation, be the crystalline powder or the loose block of white or off-white color, perhaps be aqueous solution.Amikacin is to most enterobacteriaceae lactobacteriaceaes, all have good action as escherichia coli, Klebsiella, Enterobacter, Proteus, Shigella, Salmonella, citrobacter genus, Serratia etc., Pseudomonas aeruginosa and other pseudomonass, acinetobacter, alcaligenes etc. are also had good action; Neisseria meningitidis, Diplococcus gonorrhoeae, hemophilus influenza, yersinia's genus, campylobacter fetus, tubercule bacillus and some non-tuberculous mycobacteria are belonged to the also good antibacterial action of tool.The most outstanding advantage is that amikacin is stable to the aminoglycoside inactive enzyme that many intestinal gram negative bacillis are produced, and can not lost antibacterial activity by this type of enzymatic inactivation.The mechanism of action of amikacin is the 30S subunit that acts on bacterial ribosome, suppresses the antibacterial synthetic protein.
The utility model content
Technical problem to be solved in the utility model is to provide a kind of powerful infection and suppresses film formed year slow release amikacin of bacterium living beings catheter.
The technical solution of the utility model is as follows: a kind of year slow release amikacin catheter, has the catheter body, this catheter body afterbody is connected with the gas injection arm and goes out urinary catheter, its key is: described this external surface of catheter is coated with the amikacin slow release layer, and described amikacin slow release layer is the polylactic acid-polyglycolic acid coating that is combined with amikacin.
Carry slow release amikacin catheter (New Zealand white rabbit) and external pharmacokinetics detection confirmation in body, have the effect that reduces the CAUTI incidence rate.
Described catheter body can be selected silication latex tubing or all-silicon rubber pipe for use.
The sandwich layer that described silication latex tubing is the genuine milk sebific duct and the skin of silicone rubber tube are formed.
Beneficial effect: the effect that the utlity model has obvious reduction CAUTI incidence rate.Catheter is the release amikacin of from-inner-to-outer within a certain period of time, directly kill the antibacterial around the urinary catheter, and has solved the technical barrier that amikacin can not withstand high temperatures.
Description of drawings
Fig. 1 is a structural representation of the present utility model;
Fig. 2 is the A-A cutaway view of all-silicon rubber catheter body in this utility model;
Fig. 3 is the A-A cutaway view of silication latex catheter body in this utility model.
The specific embodiment
The utility model is described in further detail below in conjunction with drawings and Examples:
As shown in Figure 1 and Figure 2, this utility model carries slow release amikacin catheter, catheter body 1 afterbody is connected with gas injection arm 4 and goes out urinary catheter 5, described catheter body 1 is the silication latex tubing, catheter 1 outer surface is coated with amikacin slow release layer 2, and described amikacin slow release layer 2 is for being combined with the polylactic acid-polyglycolic acid coating of amikacin.
As Fig. 1, shown in Figure 3, this utility model carries slow release amikacin catheter, catheter body 1 afterbody is connected with gas injection arm 4 and goes out urinary catheter 5, and described catheter body is the all-silicon rubber pipe, and the silication latex tubing is that the sandwich layer 1a of genuine milk sebific duct and the outer 1b of silicone rubber tube form.Catheter body 1 outer surface is coated with amikacin slow release layer 2, and described amikacin slow release layer 2 is for being combined with the polylactic acid-polyglycolic acid coating of amikacin.
Claims (3)
1. one kind carries slow release amikacin catheter, has catheter body (1), this catheter body (1) afterbody is connected with gas injection arm (4) and goes out urinary catheter (5), it is characterized in that: described catheter body (1) outer surface is coated with amikacin slow release layer (2), and described amikacin slow release layer (2) is for being combined with the polylactic acid-polyglycolic acid coating of amikacin.
2. according to described year slow release amikacin of claim 1 catheter, it is characterized in that: described catheter body (1) is silication latex tubing or all-silicon rubber pipe.
3. according to described year slow release amikacin of claim 2 catheter, it is characterized in that: the sandwich layer (1a) that described silication latex tubing is the natural emulsion conduit and the skin (1b) of silicone rubber tube are formed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009201284005U CN201558397U (en) | 2009-08-11 | 2009-08-11 | Sustained-releasing amikacin carrying catheter |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009201284005U CN201558397U (en) | 2009-08-11 | 2009-08-11 | Sustained-releasing amikacin carrying catheter |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201558397U true CN201558397U (en) | 2010-08-25 |
Family
ID=42623543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009201284005U Expired - Fee Related CN201558397U (en) | 2009-08-11 | 2009-08-11 | Sustained-releasing amikacin carrying catheter |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201558397U (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105792776A (en) * | 2013-10-16 | 2016-07-20 | 安东尼奥·桑布塞蒂 | PGA tubular patch and relative optional tubular support made of absorbable material for tissue reconstruction of urethral and/or ureteral removed segments |
| WO2018219035A1 (en) | 2017-05-31 | 2018-12-06 | 苏州度博迈医疗科技有限公司 | Antimicrobial silicone rubber, preparation method therefor and use thereof |
| CN114425127A (en) * | 2022-02-23 | 2022-05-03 | 山东百多安医疗器械股份有限公司 | Disposable perianal abscess antibacterial drainage tube |
-
2009
- 2009-08-11 CN CN2009201284005U patent/CN201558397U/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105792776A (en) * | 2013-10-16 | 2016-07-20 | 安东尼奥·桑布塞蒂 | PGA tubular patch and relative optional tubular support made of absorbable material for tissue reconstruction of urethral and/or ureteral removed segments |
| WO2018219035A1 (en) | 2017-05-31 | 2018-12-06 | 苏州度博迈医疗科技有限公司 | Antimicrobial silicone rubber, preparation method therefor and use thereof |
| CN114425127A (en) * | 2022-02-23 | 2022-05-03 | 山东百多安医疗器械股份有限公司 | Disposable perianal abscess antibacterial drainage tube |
| CN114425127B (en) * | 2022-02-23 | 2023-10-20 | 山东百多安医疗器械股份有限公司 | Disposable perianal abscess antibacterial drainage tube |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nickel et al. | Bacterial localization in antibiotic‐refractory chronic bacterial prostatitis | |
| Ronald et al. | Complicated urinary tract infections | |
| Warren | Catheter-associated urinary tract infections | |
| Anwar et al. | Establishment of aging biofilms: possible mechanism of bacterial resistance to antimicrobial therapy | |
| CN201558397U (en) | Sustained-releasing amikacin carrying catheter | |
| Dosunmu et al. | Silver-coated carbon nanotubes downregulate the expression of Pseudomonas aeruginosa virulence genes: a potential mechanism for their antimicrobial effect | |
| Koseoglu et al. | Ultrastructural stages of biofilm development of Escherichia coli on urethral catheters and effects of antibiotics on biofilm formation | |
| Crnich et al. | Medical device–associated infections in the long-term care setting | |
| Safdar et al. | Nosocomial infections in the intensive care unit associated with invasive medical devices | |
| He et al. | Application of a nanotechnology antimicrobial spray to prevent lower urinary tract infection: a multicenter urology trial | |
| Rubi et al. | Catheter-associated urinary tract infection (CAUTI) | |
| CN104740690B (en) | A kind of marine organisms medicament-carried nano antibacterial super slippery coating | |
| Anwar et al. | Antimicrobial resistance modulation of MDR E. coli by antibiotic coated ZnO nanoparticles | |
| Ma et al. | Chitosan nanoparticles: preparation and application in antibacterial paper | |
| Hegde et al. | Oral microflora: a comparative study in HIV and normal patients | |
| Gupta et al. | In vitro and in silico investigation of caprylic acid effect on multi drug resistant (MDR) Klebsiella pneumoniae biofilm | |
| Popova et al. | IN VITRO ANTIMICROBIAL ACTIVITY OF COLLOIDAL NANO SILVER. | |
| CN201375746Y (en) | Medical antibiosis catheter | |
| Farber et al. | The use of salicylic acid to prevent the adherence of Escherichia coli to silastic catheters | |
| Kumar et al. | Catheter-related and infusion-related sepsis | |
| Suman et al. | Anti-biofilm and anti-adherence activity of Glm-U inhibitors | |
| CN102485184A (en) | Nanometer silver antibacterial biliary duct bracket and preparation method thereof | |
| Fatima et al. | Biofilm forming bacteria isolated from medical implants | |
| CN104721176B (en) | Application of the α-ketoglutaric acid in terms of sensibility of bacteria on antibiotic is improved | |
| Godfrey et al. | Catherterisation and urinary tract infections: microbiology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100825 Termination date: 20140811 |
|
| EXPY | Termination of patent right or utility model |